Acute displacement of opioids from their receptors by administration of large doses of opioid antagonists during general anesthesia is a new approach for detoxification of patients addicted to opioids. The authors tested the hypothesis that mu-opioid receptor blockade by naloxone induces cardiovascular stimulation mediated by the sympathoadrenal system.


Heart rate, cardiac index, and intravascular pressures were measured in 10 patients addicted to opioids (drug history; mean +/- SD, 71 +/- 51 months) during a program of methadone substitution (96 +/- 57 mg/day). Cardiovascular variables and concentrations of catecholamine in plasma were measured in the awake state, during methohexital-induced anesthesia (dose, 74 +/- 44 microg x kg(-1) x min(-1)) before administration of naloxone, and repeatedly during the first 3 h of mu-opioid receptor blockade. Naloxone was administered initially in an intravenous dose of 0.4 mg, followed by incremental bolus doses (0.8, 1.6, 3.2, and 6.4 mg) at 15-min intervals until a total dose of 12.4 mg had been administered within 60 min; administration was then continued by infusion (0.8 mg/h).


Concentration of epinephrine in plasma increased 30-fold (15 +/- 9 to 458 +/- 304 pg/ml), whereas concentration of norepinephrine in plasma only increased to a minor extent (76 +/- 44 to 226 +/- 58 pg/ml, P < 0.05). Cardiac index increased by 74% (2.7 +/- 0.41 to 4.7 +/- 1.7 min(-1) x m(-2)), because of increases in heart rate (89 +/- 16 to 108 +/- 17 beats/min) and stroke volume (+44%), reaching maximum 45 min after the initial injection of naloxone. In parallel, systemic vascular resistance index decreased (-40%). Systolic arterial pressure significantly increased (113 +/- 16 to 138 +/- 16 mmHg), whereas diastolic arterial pressure did not change.


Despite barbiturate-induced anesthesia, acute mu-opioid receptor blockade in patients addicted to opioids induces profound epinephrine release and cardiovascular stimulation. These data suggest that long-term opioid receptor stimulation changes sympathoadrenal and cardiovascular function, which is acutely unmasked by mu-opioid receptor blockade. Because of the attendant cardiovascular stimulation, acute detoxification using naloxone should be performed by trained anesthesiologists or intensivists.

A MAJOR goal in the treatment of opioid addiction is to achieve abstinence from the drug. Unfortunately, classic forms of treatment are costly and not very effective, with patient drop-out rates as high as 30%. [1]These objections have encouraged many clinicians to look for innovative forms of treatment to improve outcome. In particular, mitigation of opioid withdrawal symptoms is a desirable objective because these symptoms are thought to contribute to termination of therapy by the patient. Recently, a new approach coined ultrarapid opioid detoxification has been described, with programs starting in many hospitals worldwide. [2–6]The principle idea of this approach is to antagonize any opioid effects rapidly by the administration of large doses of [micro sign]-opioid receptor antagonists. General anesthesia is induced before the start of opioid antagonization and maintained for several hours to prevent perception of withdrawal symptoms by the patient.

This treatment represents a new clinical area of interest for anesthesiologists, and it also offers the unique opportunity to assess cardiovascular effects of opioid receptor blockade during conditions of a chronically stimulated opioid receptor system in humans. In the current study, we tested the hypothesis that [micro sign]-opioid receptor blockade by intravenous administration of naloxone (Curamed, Karlsruhe, Germany) results in significant cardiovascular effects mediated by the sympathoadrenal system, despite barbiturate-induced anesthesia, and we assessed the clinical feasibility of this method.

The protocol of the study, including catheterization, blood sampling, administration of barbiturates to induce anesthesia, and the use of high doses of naloxone, was approved by the ethics committee of the University GH Essen and is consistent with the Declarations of Helsinki. All patients were informed that the treatment they would receive was not an established one, and they gave written informed consent before participating in this study.


All data are presented as mean +/- SD unless otherwise indicated. Ten patients (six women; 28 +/- 7 yr old; range, 20–39 yr old) were selected on a voluntary basis from the local methadone out-patient care unit. All had a long history of opioid abuse (73 +/- 51 months; range, 13–180 months) and were treated with orally administered methadone (96 +/- 57 mg/day; range, 50–130 mg/day for 19 +/- 19 months; range, 1–60 months). The patients were admitted to the hospital at least 1 day before treatment and were screened by clinical history, physical examination, laboratory examination, electrocardiogram, and chest radiography. Other than methadone, the patients reported that they did not consume other drugs, which was confirmed by repeated urine toxicology screens before inclusion in the study. Patients did not suffer from any overt disease, except five patients had serologic evidence of exposure to the hepatitis B or C virus without clinical or laboratory signs of impaired liver function.

The last dose of methadone was given 24 h before treatment with naloxone. Flunitrazepam (1 mg orally; Rohypnol[registered sign]; Roche, Grenzach-Wyhlen, Germany) was administered as a premedication before the patients were transferred to our intensive care unit.


After admission to the intensive care unit in the morning, a peripheral venous cannula and an arterial and a pulmonary artery catheter were inserted using local anesthesia for fluid replacement and hemodynamic monitoring. If required, mild sedation by midazolam (Dormicum[registered sign]; Roche) was provided. For prophylaxis of infection and potential development of gastrointestinal ulcers during withdrawal, 2 g ceftriaxone (Elzogram[registered sign]; Lilly, Bad Homburg, Germany) and 20 mg famotidine (Pepdul[registered sign]; MSD Chibropharm, Haar, Germany) were given. Heparin (Liquemin[registered sign]; Roche) was administered (625 U/h) for prophylaxis of thrombosis. The infusion rate of Ringer's lactate (460 +/- 98 ml/h) was adjusted to keep right atrial and pulmonary artery occlusion pressures at baseline values (central venous pressure, 7 +/- 3 mmHg; pulmonary artery, occlusion pressure, 8 +/- 3 mmHg.) Potassium chloride was infused as required (8 +/- 3 mmol/h) to maintain serum concentration of potassium close to the baseline value.

After a resting period of 30–60 min, general anesthesia was induced by 2–4 mg/kg methohexital (Brevimytal [registered sign]; Lilly) and a single dose (0.1 mg/kg) of piperocuronium (Arpilon [registered sign]; Organon, Oberschleissheim, Germany) for muscle relaxation. The trachea was intubated, and the patients were mechanically ventilated (fractional inspired oxygen concentration, 0.21–0.3; positive end-expiratory pressure [PEEP], 3 mmHg). In addition, a gastric tube, a urinary catheter, and a rectal tube were placed. Anesthesia was maintained by continuous infusion of methohexial (74 +/- 44 micro gram [center dot] kg-1[center dot] min-1) titrated to abolish corneal and glabella reflexes. This dose also suppressed the response to painful stimuli such as pinching of the skin, as studied in pilot patients. A minimum interval of 1 h was allowed to elapse before starting administration of naloxone to achieve a cardiorespiratory and anesthetic steady state. Steady-state conditions after induction of anesthesia were assumed when heart rate, arterial pressures, and cardiac index differed by < 10% between two measurements taken >or= to 30 min apart. Normocapnia was established and repeatedly confirmed by analysis of arterial blood gas.


Arterial pressures and pulmonary artery, central venous, and pulmonary artery occlusion pressures were measured by electromanometry relative to barometric pressure with transducers referenced to the midaxillary line. Heart rate was determined from the electrocardiogram (lead two) of a five-lead electrocardiogram recording system, including ST segment analysis (Sirecust 1281; Siemens, Erlangen, Germany). Cardiac output was determined in triplicate by thermodilution, injecting 10 ml of iced saline irrespective of the respiratory phase. [7,8]Calculations were performed with variables normalized to body surface area and expressed as cardiac, stroke volume, and systemic vascular resistance indices using standard formulae.

Concentrations of Catecholamine in Plasma

Concentrations of norepinephrine and epinephrine in plasma were determined by high-performance liquid chromatography with electrochemical detection (lower detection limit, 10 pg/ml; coefficient of variation, 6.2% for norepinephrine, 6.8% for epinephrine). Mixed venous blood drawn from the pulmonary artery was sampled at specified intervals into chilled tubes with ethylenediaminetetraacetic acid, cooled to +4 [degree sign]C in ice water, and immediately centrifuged. Plasma was stored at -80 [degree sign]C until analysis. [9] 

Study Protocol

Treatment with naloxone was started after achieving steady-state conditions during anesthesia (see previous section) using a first dose of 0.4 mg administered intravenously. Four additional naloxone bolus doses of increasing dose amount (0.8, 1.6, 3.2, and 6.4 mg) were injected at 15-min intervals. Accordingly, a total of 12.4 mg of naloxone was given during a 60-min period. This stepwise approach was chosen for safety reasons because complications after injection of naloxone have been described, [10–16]and effects in our patients were considered unpredictable.

Seventy-five minutes after the first dose of naloxone, an infusion of naloxone was started in a dose of 0.8 mg/h for 24 h. [micro sign]-opioid receptor blockade was continued with 50 mg/d naltrexon administered via the gastric tube starting 12 h after the first injection of naloxone.

Cardiovascular variables were assessed before induction of anesthesia (patient awake), at least twice within the period before application of naloxone, and 15 min after each bolus dose of naloxone, i.e., after 15, 30, 45, 60, and 75 min, and 120 and 180 min after the initial administration of naloxone. At the same time, pulmonary arterial blood was collected for determination of concentrations of epinephrine and norepinephrine in plasma.

Continuous infusion of methohexital was stopped after the 180-min observation period. To attenuate withdrawal symptoms after anesthesia, clonidine ([nearly =] 2 micro gram [center dot] kg-1[center dot] h-1) was given intravenously until the patient was discharged to the psychiatric ward the next morning, as required.

Statistical Analysis

Differences in mean values of variables over time were determined by one-way repeated-measures analysis of variance followed by Fisher's post hoc test. The following a priori null hypotheses were tested: There is no difference in means of variables at baseline (before administration of naloxone) compared with observations (1) after administration of naloxone and (2) before induction of anesthesia. A null hypothesis was rejected, and statistical significance assumed with an alpha error (P value) < 0.05.

Concentrations of Catecholamine in Plasma

Concentration of epinephrine in plasma was 15 +/- 9 pg/ml, and concentration of norepinephrine in plasma was 76 +/- 44 pg/ml after achieving steady-state conditions after induction of anesthesia. Administration of naloxone induced a 30-fold increase in concentration of epinephrine in plasma (to 458 +/- 304 pg/ml and a threefold significant increase in concentration of norepinephrine in plasma (to 226 +/- 58 pg/ml). Peak concentrations were attained after 60–75 min and remained significantly increased compared with baseline values until the end of the observation period (Figure 1).

Cardiovascular Alterations

Administration of naloxone markedly increased heart rate within 1–2 min, from 89 +/- 16 to a plateau of 108 +/- 17 beats/min with no further increase. Stroke volume index also increased from 31 +/- 8 to 45 +/- 11 ml [center dot] m-2(P < 0.05) but in a more gradual fashion. Increased heart rate and stroke volume index resulted in a marked increase in cardiac index, from 2.7 +/- 0.41 to 4.7 +/- 1.7 min (-1)[center dot] m-2(+74%), reaching a plateau after [nearly =] 45 min (Figure 2). In parallel, systemic vascular resistance index decreased from 2,484 +/- 762 to 1,495 +/- 539 dyne [center dot] s [center dot] cm-5[center dot] m-2(P < 0.05;Figure 2).

Systolic arterial pressure significantly increased from 113 +/- 16 +/- 5 to 138 +/- 16 mmHg, reaching maximum 15–30 min after initiation of naloxone administration, whereas diastolic arterial pressure remained unchanged (71 +/- 16 vs. 80 +/- 16 mmHg after administration of naloxone, P = 0.13;Figure 3).

Mean pulmonary artery pressure increased from 15 +/- 5 to 20 +/- 4 mmHg (P < 0.05) at 30 min, whereas pulmonary vascular resistance remained normal and unchanged throughout the observation period.

Clinical Observations

The clinical signs of [micro sign]-opioid receptor blockade were observed in all patients: marked gastrointestinal secretion with 500–1,000 ml of fluids draining from the gastric tube and rectal discharges of 200–500 ml during the 180-min observation period.

None of the patients moved, coughed, or vomited during the observation period after administration of naloxone. Further, all patients showed miosis and absence of the corneal and glabella reflexes during anesthesia and administration of naloxone until sedation was terminated.

After discontinuation of methohexital 180 min after the first dose of naloxone, patients started sweating, hyperventilating, moving, and coughing. Patients were extubated 264 +/- 219 min after administration of methohexital was stopped. No complications attributable to treatment with naloxone were observed.

This study is the first to assess concentrations of catecholamine in plasma and cardiovascular alterations after [micro sign]-opioid receptor blockade in patients addicted to opioids. These results are clinically important for evaluation of potential cardiovascular risk and for guiding care and improving patient safety during acute detoxification in those addicted to opioids. This study represents a unique setting for assessment of the effects of acute [micro sign]-opioid receptor blockade in humans with a chronically stimulated opioid receptor system.

Most important, a 30-fold increase in concentration of epinephrine in plasma, a small increase in concentration of norepinephrine in plasma, and profound cardiovascular alterations were observed after [micro sign]-opioid receptor blockade despite maintenance of general anesthesia. Because of the attendant cardiovascular stimulation, we suggest that acute detoxification of patients addicted to opioids should be performed by trained anesthesiologists or intensivists.

Critique of Methods

Sympathetic nervous system activity, concentrations of catecholamine in plasma, and cardiovascular variables are potentially influenced by anesthesia, altered cardiac filling, and changes in arterial blood gas tensions induced by mechanical ventilation. [10–12]Barbiturate-induced anesthesia abolished corneal and glabella reflexes. The absence of circulatory stress during anesthesia at baseline before administration of naloxone was indicated by constantly decreased arterial pressure and stroke volume index and by low concentrations of catecholamine in plasma. [13,14]The increased heart rate observed after induction of anesthesia by methohexital is most likely due to its parasympatholytic activity. [15,16]To minimize changes that may alter sympathetic nervous system activity, central venous and pulmonary artery occlusion pressures were maintained by administration of Ringer's lactate solution, and normocarbia was established.

Effects of receptor antagonists depend on concentrations of receptor agonist and antagonist. In our patients, [micro sign]-opioid receptor blockade induced marked gastrointestinal secretion, indicating that effective doses of naloxone had been injected. Finally, when assessing the effect of long-term opioid receptor stimulation and blockade in addicted patients, interference with other drugs must be considered. In our study, we carefully selected only patients addicted to one opioid that was substituted with orally administered methadone and confirmed the absence of intake of other drugs by repeated drug screening.

In anesthetic practice, the [micro sign]-opioid receptor antagonist naloxone is the drug of choice for reversing opioid-induced respiratory depression. Rare but serious complications have been reported after [micro sign]-opioid receptor antagonization, however, including marked arterial hypertension, pulmonary edema, and sudden death after administration of even small doses of naloxone. [17–23]The exact mechanisms responsible for these adverse effects are unknown, and no data have been reported regarding cardiovascular alterations in patients addicted to opioids. Accordingly, to minimize potential complications, we administered naloxone in a stepwise fashion.

Interpretation of Results

Conventional detoxification from long-term intake of opioids in addicted patients is accompanied by unpleasant withdrawal symptoms and drop-out rates of up to 30% during initial therapy. [1]It is widely accepted that the severity of withdrawal symptoms during detoxification is positively correlated with the frequency of unsuccessful therapy. Accordingly, general anesthesia is induced before [micro sign]-opioid receptor blockade in the approach described here of acute opioid detoxification to prevent perception of withdrawal symptoms by the patient. The purpose of administering high doses of naloxone is to terminate [micro sign]-opioid receptor stimulation rapidly and to prepare maintenance of prolonged [micro sign]-opioid receptor blockade by naltrexone while minimizing withdrawal symptoms, e.g., by administration of the alpha2-receptor agonist clonidine. Studies with this new approach have been aimed mainly at psychiatric variables, and, [2–6,23–25]to our knowledge, the cardiovascular effects of high-dose naloxone in patients addicted to opioids have not been described previously.

Although naloxone, even when injected in high doses (0.15 mg/kg) in healthy volunteers, does not increase concentrations of epinephrine in plasma, [26–28]heart rate, arterial or central venous pressures, or efferent sympathetic nerve activity to calf muscle in the absence of opioid receptor agonist stimulation, [29,30]we observed a 30-fold increase in the concentration of epinephrine in plasma and a threefold significant increase in the concentration of norepinephrine in plasma. Maximum concentrations of catecholamine in plasma were attained 45–60 min after the initial injection of naloxone with a total dose of 2.8–6.0 mg naloxone administered. In parallel, cardiac output (+74%), heart rate (+24%), stroke volume (+44%), and systolic arterial pressure (+22%) increased, whereas systemic vascular resistance decreased (-40%).

It is noteworthy that a similar pattern of changes in the concentrations of catecholamine in plasma was observed earlier in awake morphine-dependent rats after administration of naloxone and was abolished by removal of the adrenal glands, suggesting that the increase in concentration of epinephrine in plasma is due to increased adrenal release of epinephrine. [31,32] 

Cardiovascular changes observed in our study are in line with beta-adrenoceptor effects of epinephrine and, accordingly, may be mediated by the determined alterations in concentrations of catecholamine in plasma. This hypothesis is supported by other data.

Infusion of epinephrine in awake volunteers increased concentration of epinephrine in plasma from 50 to 480 pg/ml, i.e., to concentrations very similar to those observed in our study after [micro sign]-opioid receptor blockade by naloxone; increased heart rate by 24%, cardiac output by 74%, and stroke volume by 40%; and decreased systemic vascular resistance by 31%. [33]Most of these cardiovascular changes were attained at plasma concentrations of 260 pg/ml, with few additional changes when the concentration of epinephrine in plasma was further increased. [33]Concentrations of norepinephrine in plasma also increased (by 60%) during infusion of epinephrine, possibly secondary to the decrease in systemic vascular resistance induced by epinephrine, and this increase in concentration can be considered hemodynamically important. [33]Accordingly, these data taken together support the assumption that cardiovascular stimulation observed in our study after [micro sign]-opioid receptor blockade is mediated to a major extent by increased concentrations of epinephrine in plasma.

Although our study design does not allow us to pinpoint responsible mechanisms for the profound increase in the concentration of epinephrine in plasma after [micro sign]-opioid receptor blockade by naloxone in patients addicted to opioids, potential mechanisms include direct effects of naloxone, [micro sign]-opioid receptor antagonization on the adrenal medulla, [34]and neurally mediated changes of central sympathetic outflow, e.g., by disinhibition and resetting of cardiopulmonary baroreflexes. [35]The 30-fold increase in the concentration of epinephrine in plasma in the absence of a quantitatively similar increase in that for norepinephrine is rather atypical for a generalized activation of the sympathetic nervous system.

Despite maintenance of general anesthesia, [micro sign]-opioid receptor blockade in patients addicted to opioids undergoing methadone substitution induces a profound increase in the concentration of epinephrine in plasma and cardiovascular stimulation in a pattern similar to that observed with infusion of epinephrine in healthy volunteers. Because of the attendant cardiovascular changes, we suggest that acute detoxification of patients addicted to opioids should be handled by trained anesthesiologists or intensivists.

The authors thank Matthias Steimer and the intensive care nursing staff for excellent nursing and assistance; Marc Achilles for assistance in performing hemodynamic measurements and blood sampling; and the technicians of the biochemistry laboratory for determination of concentrations of catecholamine in plasma.

Mattick RP: Are detoxification programs effective? Lancet 1996; 347:97-100.
Loimer N, Schmid RW, Presslich O, Lenz K: Continuous naloxone administration suppresses opiate withdrawal symptoms in human opiate addicts during detoxification treatment. J Psychiatr Res 1989; 23:81-6.
Loimer N, Schmidt R, Lenz K, Presslich O, Grunberger J: Acute blocking of naloxone-precipitated opiate withdrawal symptoms by methohexitone. Br J Psychiatry 1990; 157:748-52.
Loimer N, Hofmann P, Chaudhry H: Ultrashort noninvasive opiate detoxification. Am J Psychiatry 1993; 150:839.
Gossop M, Griffiths P, Bradley B, Strang J: Opiate withdrawal responses to 10-day and 21-day methadone withdrawal programs. Br J Psychiatry 1991; 148:1291-300.
Legarda JJ, Gossop M: A 24-h inpatient detoxification treatment for heroin addicts: A preliminary investigation. Drug Alcohol Depend 1994; 35:91-3.
Ganz W, Swan HJC: Measurement of blood flow by thermodilution. Am J Cardiol 1972; 29:241-6.
Jansen JRC, Schreuder JJ, Settels JJ, Kloek JJ, Versprille AA: An adequate strategy for the thermodilution technique during mechanical ventilation. Intensive Care Med 1990: 16:422-5.
Bauch HJ, Kelsch U, Hauss WH: Einfache, schnelle, selektive und quantitative Bestimmung von Adrenalin und Noradrenalin im Plasma durch Kombination von Flussigkeitsextraktion, HPLC-Trennung und elektrochemischer Detektion. J Clin Chem Clin Biochem 1986; 24:651-8.
Victor RG, Leimbach WN Jr: Effects of lower body negative pressure on sympathetic discharge to leg muscles in humans. J Appl Physiol 1987; 63:2558-62.
Somers VK, Mark AL, Zavala DC, Abboud FM: Contrasting effects of hypoxia and hypercapnia on ventilation and sympathetic activity in humans. J Appl Physiol 1989; 67:2101-6.
Macefield VG, Wallin BG: Modulation of muscle sympathetic activity during spontaneous and artificial ventilation and apnoea in humans. J Autonom Nerv Syst 1995; 53:137-47.
Sellgren J, Ponten J, Wallin BG: Characteristics of muscle sympathetic activity during general anaesthesia in humans. Acta Anaesthesiol Scand 1992; 36:336-45.
Ebert TJ, Kanitz DD, Kampine JP: Inhibition of sympathetic neural outflow during thiopental anesthesia in humans. Anesth Analg 1990; 71:319-26.
Peiss CN, Manning JW: Effects of sodium pentobarbital on electrical and reflex activation of the cardiovascular system. Circ Res 1964; 14:228-35.
Inoue K, Amdt JO: Efferent vagal discharge and heart rate in response to methohexitone, althesin, ketamine and etomidate in cats. Br J Anaesth 1982; 54:1105-16.
Tanaka GY: Hypertensive reaction to naloxone. JAMA 1974; 228:25-6.
Flacke JW, Flacke WE, Williams GD: Acute pulmonary edema following reversal of high-dose morphine anesthesia. Anesthesiology 1977; 47:376-8.
Andree RA: Sudden death following naloxone administration. Anesth Analg 1980; 59:782-4.
Taff RH: Pulmonary edema following low-dose naloxone administration. Anesthesiology 1983; 59:576-7.
Partridge BL, Ward CF: Pulmonary edema following low-dose naloxone administration. Anesthesiology 1986; 65:709-10.
Johnson C, Mayer P, Grosz D: Pulmonary edema following naloxone administration in a healthy orthopedic patient. J Clin Anesth 1995; 7:356-7.
Pfab T, Hirtl C, Hibler A, Felgenheuer N, Chlistalla J, Zilker TH: Der Antagonist-induzierte, Narkose-gestutzte Opiat-Schnellentzug (AINOS). Munch Med Wochenschr 1996; 138:781-6.
Resnick RB, Kestenbaum RS, Washton A, Poole D: Naloxone-precipitated withdrawal: A method for rapid induction onto naltrexone. Clin Pharmacol Ther 1977; 21:409-13.
Dettling M, Tretter F: Der Opiatentzug in Narkose (forcierter Narkosentzug, “Turboentzug”) bei Opiatabhangigkeit. Nervenarzt 1996; 67:805-10.
Estilo AE, Cottrell JE: Hemodynamic and catecholamine changes after administration of naloxone. Anesth Analg 1982; 61:349-53.
Mannelli M, Maggi M, De Feo ML, Cuomo S, Delitala G, Giusti G, Serio M: Effects of naloxone on catecholamine plasma levels in adult men: A dose-response study. Acta Endocrinologica 1984; 106:357-61.
Bouloux PM, Grossman A, Al-Damluji S, Bailey T, Besser M: Enhancement of the sympathoadrenal response to the cold-pressure test by naloxone in man. Clin Sci 1985; 69:365-8.
Farrell PA, Ebert TJ, Kampine JP: Naloxone augments muscle sympathetic nerve activity during isometric exercise in humans. Am J Physiol 1991; 260:E379-88.
Schobel HP, Oren RM, Mark AAL, Ferguson DW: Naloxone potentiates cardiopulmonary baroreflex sympathetic control in normal humans. Circ Res 1992; 70:172-83.
Delle M, Ricksten SE, Haggendal J, Olsson K, Skarphedinson JO, Thoren P: Regional changes in sympathetic nerve activity and baroreceptor reflex function and arterial plasma levels of catecholamines, renin and vasopressin during naloxone-precipitated morphine withdrawal in rats. J Pharmacol Exp Ther 1990; 253:646-54.
Chang APL, Dioxon WR: Role of plasma catecholamines in eliciting cardiovascular changes seen during naloxone-precipitated withdrawal in conscious, unrestrained morphine-dependent rats. J Pharmacol Exp Ther 1990; 254:857-63.
Stratton JR, Pfeifer MA, Ritcher JL, Halter JB: Hemodynamic effects of epinephrine: Concentration-effect study in humans. J Appl Physiol 1985; 58:1199-206.
Kimura T, Katoh M, Satoh S: Inhibition by opioid agonists and enhancement by antagonists of the release of catecholamines from the dog adrenal gland in response to splanchnic nerve stimulation: Evidence for the functional role of opioid receptors. J Pharmacol Exp Ther 1988; 244:1098-102.
Schobel HP, Oren RM, Mark AAL, Ferguson DW: Naloxone potentiates cardiopulmonary baroreflex sympathetic control in normal humans. Circ Res 1992; 70:172-83.